What is the appropriate oral treatment for typhoid fever?

Oral Treatment for Typhoid Fever

For uncomplicated typhoid fever, azithromycin (1g on day 1, then 500mg daily for 6 more days) is the preferred oral treatment in most endemic regions due to widespread fluoroquinolone resistance, with cefixime as an alternative if azithromycin resistance is present. 1

Treatment Algorithm Based on Resistance Patterns

First-Line Oral Options (Choose Based on Local Susceptibility):

For Fully Susceptible Strains:

• Fluoroquinolones (ciprofloxacin 500mg twice daily for 7 days OR ofloxacin 400mg twice daily for 14 days) remain effective when the organism is fully susceptible 1, 2
• However, this scenario is increasingly rare in endemic regions

For Nalidixic Acid-Resistant or Reduced Fluoroquinolone Susceptibility (Most Common):

• Azithromycin is superior: 1g on day 1, then 500mg daily for 6 days 1, 3
• Evidence shows lower clinical failure rates (OR 0.48) and fewer relapses (OR 0.09) compared to fluoroquinolones and ceftriaxone respectively 1
• Critical caveat: Relapse occurs when ciprofloxacin MIC exceeds 0.12 mg/L, making fluoroquinolones unreliable in these cases 4

For Multidrug-Resistant (MDR) Strains:

• Cefixime 20mg/kg/day in two divided doses (maximum 400mg twice daily) for 7 days 1
• Alternative: Azithromycin if cephalosporin resistance is not present

For Extensively Drug-Resistant (XDR) Strains:

• Oral options are extremely limited 5, 6
• May require IV therapy with meropenem, then transition to azithromycin if susceptible
• Emerging option: oral carbapenem (tebipenem) under investigation 5

Key Clinical Considerations

Why Fluoroquinolones Are No Longer First-Line:

The WHO 2012 guidelines 1 recommended fluoroquinolones as first-line, but this recommendation is outdated. Widespread emergence of reduced fluoroquinolone susceptibility, particularly from South Asia, has rendered them unreliable 4, 6. The 2024 guideline evidence shows azithromycin outperforms fluoroquinolones in regions with nalidixic acid resistance 1.

Treatment Duration and Response:

• Expect fever defervescence within 3-5 days with appropriate therapy 2, 7
• Complete the full 7-day course to prevent relapse
• Clinical failure by day 7-8 suggests resistance or complications

Common Pitfalls to Avoid:

1. Don't use ciprofloxacin empirically in endemic regions - High rates of reduced susceptibility make treatment failure likely 4, 6
2. Don't underdose azithromycin - The loading dose of 1g on day 1 is critical for adequate tissue penetration 3
3. Don't assume older antibiotics work - Chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole resistance is widespread in endemic areas 8, 7

Geographic Considerations:

South Asia (Pakistan, India, Bangladesh, Nepal):

• Highest rates of fluoroquinolone resistance and emerging XDR strains 6, 9
• Azithromycin or cefixime should be first-line
• Pakistan has ongoing XDR outbreak since 2016 6

Other Endemic Regions:

• Resistance patterns vary; obtain local antibiogram data when possible
• When unavailable, azithromycin remains the safest empiric choice 1

Emerging Strategy Under Investigation:

Combination therapy with azithromycin PLUS cefixime is being studied in the ACT-SA trial 5, 9. The rationale is that azithromycin targets intracellular bacteria while cefixime targets extracellular organisms, potentially improving cure rates and limiting resistance emergence. However, this is not yet standard of care pending trial results.

When to Escalate to IV Therapy:

Switch to IV ceftriaxone (4g daily) if:

• Severe illness with complications (confusion, GI bleeding, perforation)
• Unable to tolerate oral medications
• Clinical failure after 5-7 days of appropriate oral therapy
• Known XDR strain 4, 6